Targeted Therapy in HR+ HER2- Metastatic Breast Cancer: Current Clinical Trials and Their Implications for CDK4/6 Inhibitor Therapy and beyond Treatment Options.

Cancers (Basel) · 2021 · PMC8656925 · PMID 34885105

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

To date, we have seen statistically relevant longer OS in the few studies with abemaciclib and ribociclib, but not with palbocilicib, which only showed a positive trend [ 28 ].

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.